Pasi A. Jänne
Co-discovered EGFR mutations in lung cancer and has led the drug development that followed, from osimertinib to KRAS G12C inhibitors.
Co-author of the 2004 discovery that EGFR mutations predict gefitinib response; led FLAURA2 (osimertinib plus chemotherapy) and the KRYSTAL-1 adagrasib lung study; directs Dana-Farber's thoracic oncology centre.
| Title | Journal | Year |
|---|---|---|
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | New England Journal of Medicine | 2004 |
| Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation | New England Journal of Medicine | 2022 |
| Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC | New England Journal of Medicine | 2023 |
Pages like this
not linked directly; found by shared links- IdeaTest alternating drug schedules against giving both drugs at once
Shares FLAURA2, Osimertinib, Non-small-cell lung cancer.
- TrialKRYSTAL-12
Shares Adagrasib, KRAS, Non-small-cell lung cancer.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonJohn V. Heymach
Shares Osimertinib, KRAS, EGFR, Non-small-cell lung cancer.
- PersonYi-Long Wu
Shares International Association for the Study of Lung Cancer, Osimertinib, EGFR, Non-small-cell lung cancer.
- TrialKrascendo 1
Shares Adagrasib, KRAS, Non-small-cell lung cancer.
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
Shares International Association for the Study of Lung Cancer, KRAS, EGFR, Non-small-cell lung cancer.
- PersonJean-Charles Soria
Shares Osimertinib, EGFR, Non-small-cell lung cancer.